CR20120177A - Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes - Google Patents

Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes

Info

Publication number
CR20120177A
CR20120177A CR20120177A CR20120177A CR20120177A CR 20120177 A CR20120177 A CR 20120177A CR 20120177 A CR20120177 A CR 20120177A CR 20120177 A CR20120177 A CR 20120177A CR 20120177 A CR20120177 A CR 20120177A
Authority
CR
Costa Rica
Prior art keywords
diabetes
spiropiperidine
treatment
same
new compounds
Prior art date
Application number
CR20120177A
Other languages
English (en)
Spanish (es)
Inventor
Chafiq Hamdouchi
Jayana Pankaj Lineswala
Pranab Maiti
Original Assignee
Lilly Co Eli
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120177(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Memory Pharm Corp filed Critical Lilly Co Eli
Publication of CR20120177A publication Critical patent/CR20120177A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CR20120177A 2009-10-15 2012-04-12 Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes CR20120177A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US30333410P 2010-02-11 2010-02-11

Publications (1)

Publication Number Publication Date
CR20120177A true CR20120177A (es) 2012-06-06

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120177A CR20120177A (es) 2009-10-15 2012-04-12 Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes

Country Status (24)

Country Link
US (1) US8383642B2 (US07846941-20101207-C00217.png)
EP (1) EP2488500A1 (US07846941-20101207-C00217.png)
JP (1) JP2013508279A (US07846941-20101207-C00217.png)
KR (1) KR20120051777A (US07846941-20101207-C00217.png)
CN (1) CN102574807A (US07846941-20101207-C00217.png)
AR (1) AR078522A1 (US07846941-20101207-C00217.png)
AU (1) AU2010307094A1 (US07846941-20101207-C00217.png)
BR (1) BR112012008889A2 (US07846941-20101207-C00217.png)
CA (1) CA2777775A1 (US07846941-20101207-C00217.png)
CL (1) CL2012000921A1 (US07846941-20101207-C00217.png)
CO (1) CO6531458A2 (US07846941-20101207-C00217.png)
CR (1) CR20120177A (US07846941-20101207-C00217.png)
DO (1) DOP2012000105A (US07846941-20101207-C00217.png)
EA (1) EA201270560A1 (US07846941-20101207-C00217.png)
EC (1) ECSP12011799A (US07846941-20101207-C00217.png)
IL (1) IL218344A0 (US07846941-20101207-C00217.png)
MA (1) MA33662B1 (US07846941-20101207-C00217.png)
MX (1) MX2012004420A (US07846941-20101207-C00217.png)
NZ (1) NZ598972A (US07846941-20101207-C00217.png)
PE (1) PE20121437A1 (US07846941-20101207-C00217.png)
TN (1) TN2012000152A1 (US07846941-20101207-C00217.png)
TW (1) TW201124415A (US07846941-20101207-C00217.png)
WO (1) WO2011046851A1 (US07846941-20101207-C00217.png)
ZA (1) ZA201202560B (US07846941-20101207-C00217.png)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2456515T3 (es) 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Derivados de pirimidindiona fusionados como moduladores de TRPA1
PT2411395E (pt) 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
NZ601408A (en) 2009-12-25 2013-12-20 Mochida Pharm Co Ltd Novel 3-hydroxy-5-arylisothiazole derivative
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体
CA2829351A1 (en) 2011-03-11 2012-09-20 Intercontinental Great Brands Llc System and method of forming multilayer confectionery
JP5420796B2 (ja) 2011-04-27 2014-02-19 持田製薬株式会社 新規3−ヒドロキシイソチアゾール1−オキシド誘導体
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
AR087451A1 (es) 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
CN104812748B (zh) 2012-11-16 2017-10-24 百时美施贵宝公司 二氢吡唑gpr40调节剂
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
CN105722841A (zh) * 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
CA2960944C (en) * 2014-10-17 2019-09-10 Hyundai Pharm Co., Ltd. Use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivatives in combination with a secondary active ingredient for the treatment of metabolic diseases
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
DK3737470T5 (da) 2018-01-08 2024-05-27 Celon Pharma Sa 3-phenyl-4-hexynsyrederivater som gpr40-agonister
SG11202007646UA (en) 2018-02-13 2020-09-29 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
TWI732245B (zh) 2018-07-13 2021-07-01 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
EP4172162A1 (en) 2020-06-26 2023-05-03 Kallyope, Inc. Ampk activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2316559T3 (es) * 2001-04-18 2009-04-16 Euro-Celtique S.A. Compuestos espiroindeno y espiroindano.
RU2005134230A (ru) * 2003-04-04 2006-05-10 Мерк энд Ко., Инк. (US) Ацилированные производные спиропиперидина как агонисты рецептора меланокортина-4
CA2544602A1 (en) * 2003-11-04 2005-05-26 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
KR20070004769A (ko) 2004-02-27 2007-01-09 암젠 인코포레이션 대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법
WO2005095338A1 (ja) * 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
CA2621949A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
NZ584161A (en) 2007-10-26 2011-12-22 Japan Tobacco Inc Spiro-ring compound and use thereof for medical purposes
CA2706391A1 (en) * 2007-11-21 2009-05-28 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
US8383642B2 (en) 2013-02-26
AR078522A1 (es) 2011-11-16
CN102574807A (zh) 2012-07-11
CL2012000921A1 (es) 2012-09-14
ECSP12011799A (es) 2012-07-31
EP2488500A1 (en) 2012-08-22
TW201124415A (en) 2011-07-16
IL218344A0 (en) 2012-04-30
CO6531458A2 (es) 2012-09-28
ZA201202560B (en) 2013-09-25
TN2012000152A1 (en) 2013-12-12
BR112012008889A2 (pt) 2019-09-24
US20110092531A1 (en) 2011-04-21
EA201270560A1 (ru) 2012-09-28
MX2012004420A (es) 2012-05-08
MA33662B1 (fr) 2012-10-01
CA2777775A1 (en) 2011-04-21
PE20121437A1 (es) 2012-10-26
NZ598972A (en) 2013-06-28
WO2011046851A1 (en) 2011-04-21
DOP2012000105A (es) 2013-01-31
AU2010307094A1 (en) 2012-04-19
JP2013508279A (ja) 2013-03-07
KR20120051777A (ko) 2012-05-22

Similar Documents

Publication Publication Date Title
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
UY32062A (es) Inhibidores de beta-secretasa
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
DOP2011000260A (es) Pirimidinas fusionadas
CL2014001154A1 (es) Compuestos derivados antibioticos de 2-oxo-oxazolidin-3,5-diilo de formula i; composicion farmaceutica; uso para la prevencion o tratamiento de una infeccion bacteriana.
DOP2014000018A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
ECSP10010168A (es) Benzotiazolas como moduladores del receptor de ghrelina
ECSP13012653A (es) COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO Y SU USO PARA EL TRATAMIENTO DE CÁNCER
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
CO6382120A2 (es) Compuestos ciclopropilo
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
CL2007003806A1 (es) Compuestos derivados de n-(2h-pirazol-3-il)-amida, inhibidores del fgfr; composicion farmaceutica que comprende a dichos compuestos; su proceso de preparacion; y su uso para el tratamiento del cancer.
CO6300947A2 (es) Derivados de 6,7-dialcoxi quinazolina utiles para el tratamiento de cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)